New-generation Antipsychotics and Cardiovascular Risk

Purpose of Review: To critically review the current landscape of literature on cardiotoxicity of “new-generation antipsychotics,” defined as those approved by the Food and Drug Administration in the last 10 years. Recent Findings: There is a paucity of data regarding the cardiovascular risks of these medications. Based on the investigations that have been published, iloperidone appears to be the greatest risk of corrected QT prolongation followed by asenapine whereas lurasidone, cariprazine, and brexpiprazole were not found to have significant effects on corrected QT. However, the evidence was low quality. In terms of metabolic effects, asenapine, iloperidone, cariprazine, and brexpiprazole all had mild to moderate effects whereas lurasidone had no significant effects observed. Summary: Further investigation is warranted for all of these medications to better understand their cardiovascular effects.

Duke Scholars

Author Aishwarya K Rajagopalan Psychiatry, Child & Family Mental Health & Community Psychia ...